Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
RDNT vs AORT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
RDNT vs AORT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Devices |
| Market Cap | $4.45B | $1.72B |
| Revenue (TTM) | $2.04B | $459M |
| Net Income (TTM) | $47M | $12M |
| Gross Margin | 11.2% | 63.8% |
| Operating Margin | 3.0% | 7.4% |
| Forward P/E | 91.8x | 98.7x |
| Total Debt | $1.86B | $292M |
| Cash & Equiv. | $767M | $65M |
RDNT vs AORT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| RadNet, Inc. (RDNT) | 100 | 337.4 | +237.4% |
| Artivion, Inc. (AORT) | 100 | 155.7 | +55.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RDNT vs AORT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RDNT is the clearest fit if your priority is long-term compounding.
- 9.5% 10Y total return vs AORT's 188.9%
- Lower P/E (91.8x vs 98.7x)
AORT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 4 yrs, beta 0.63
- Rev growth 13.6%, EPS growth 165.6%, 3Y rev CAGR 12.0%
- Lower volatility, beta 0.63, Low D/E 65.2%, current ratio 2.99x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.6% revenue growth vs RDNT's 11.5% | |
| Value | Lower P/E (91.8x vs 98.7x) | |
| Quality / Margins | 2.5% margin vs RDNT's 2.3% | |
| Stability / Safety | Beta 0.63 vs RDNT's 1.43, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +24.7% vs RDNT's +4.6% | |
| Efficiency (ROA) | 1.3% ROA vs RDNT's 1.3%, ROIC 3.2% vs 2.0% |
RDNT vs AORT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RDNT vs AORT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AORT leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RDNT is the larger business by revenue, generating $2.0B annually — 4.4x AORT's $459M. Profitability is closely matched — net margins range from 2.5% (AORT) to 2.3% (RDNT).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.0B | $459M |
| EBITDAEarnings before interest/tax | $214M | $51M |
| Net IncomeAfter-tax profit | $47M | $12M |
| Free Cash FlowCash after capex | -$178M | $13M |
| Gross MarginGross profit ÷ Revenue | +11.2% | +63.8% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +7.4% |
| Net MarginNet income ÷ Revenue | +2.3% | +2.5% |
| FCF MarginFCF ÷ Revenue | -8.7% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.8% | +17.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -114.1% | +3.5% |
Valuation Metrics
RDNT leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, RDNT's 25.9x EV/EBITDA is more attractive than AORT's 39.5x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $4.5B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | -230.00x | 168.52x |
| Forward P/EPrice ÷ next-FY EPS est. | 91.75x | 98.69x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 25.88x | 39.50x |
| Price / SalesMarket cap ÷ Revenue | 2.18x | 3.89x |
| Price / BookPrice ÷ Book value/share | 3.19x | 3.72x |
| Price / FCFMarket cap ÷ FCF | 52.01x | — |
Profitability & Efficiency
AORT leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
RDNT delivers a 3.8% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $3 for AORT. AORT carries lower financial leverage with a 0.65x debt-to-equity ratio, signaling a more conservative balance sheet compared to RDNT's 1.37x. On the Piotroski fundamental quality scale (0–9), AORT scores 6/9 vs RDNT's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +3.8% | +2.7% |
| ROA (TTM)Return on assets | +1.3% | +1.3% |
| ROICReturn on invested capital | +2.0% | +3.2% |
| ROCEReturn on capital employed | +2.1% | +3.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.37x | 0.65x |
| Net DebtTotal debt minus cash | $1.1B | $227M |
| Cash & Equiv.Liquid assets | $767M | $65M |
| Total DebtShort + long-term debt | $1.9B | $292M |
| Interest CoverageEBIT ÷ Interest expense | 1.46x | 1.28x |
Total Returns (Dividends Reinvested)
Evenly matched — RDNT and AORT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RDNT five years ago would be worth $24,710 today (with dividends reinvested), compared to $11,543 for AORT. Over the past 12 months, AORT leads with a +24.7% total return vs RDNT's +4.6%. The 3-year compound annual growth rate (CAGR) favors AORT at 34.3% vs RDNT's 26.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -19.0% | -20.4% |
| 1-Year ReturnPast 12 months | +4.6% | +24.7% |
| 3-Year ReturnCumulative with dividends | +100.0% | +142.2% |
| 5-Year ReturnCumulative with dividends | +147.1% | +15.4% |
| 10-Year ReturnCumulative with dividends | +947.4% | +188.9% |
| CAGR (3Y)Annualised 3-year return | +26.0% | +34.3% |
Risk & Volatility
AORT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AORT is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RDNT's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AORT currently trades 73.3% from its 52-week high vs RDNT's 67.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 0.63x |
| 52-Week HighHighest price in past year | $85.84 | $48.25 |
| 52-Week LowLowest price in past year | $50.76 | $26.84 |
| % of 52W HighCurrent price vs 52-week peak | +67.0% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 42.1 |
| Avg Volume (50D)Average daily shares traded | 822K | 385K |
Analyst Outlook
AORT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates RDNT as "Buy" and AORT as "Buy". Consensus price targets imply 60.0% upside for RDNT (target: $92) vs 46.9% for AORT (target: $52).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $92.00 | $52.00 |
| # AnalystsCovering analysts | 11 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 4 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
AORT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RDNT leads in 1 (Valuation Metrics). 1 tied.
RDNT vs AORT: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is RDNT or AORT a better buy right now?
For growth investors, Artivion, Inc.
(AORT) is the stronger pick with 13. 6% revenue growth year-over-year, versus 11. 5% for RadNet, Inc. (RDNT). Artivion, Inc. (AORT) offers the better valuation at 168. 5x trailing P/E (98. 7x forward), making it the more compelling value choice. Analysts rate RadNet, Inc. (RDNT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RDNT or AORT?
On forward P/E, RadNet, Inc.
is actually cheaper at 91. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RDNT or AORT?
Over the past 5 years, RadNet, Inc.
(RDNT) delivered a total return of +147. 1%, compared to +15. 4% for Artivion, Inc. (AORT). Over 10 years, the gap is even starker: RDNT returned +947. 4% versus AORT's +188. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RDNT or AORT?
By beta (market sensitivity over 5 years), Artivion, Inc.
(AORT) is the lower-risk stock at 0. 63β versus RadNet, Inc. 's 1. 43β — meaning RDNT is approximately 126% more volatile than AORT relative to the S&P 500. On balance sheet safety, Artivion, Inc. (AORT) carries a lower debt/equity ratio of 65% versus 137% for RadNet, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RDNT or AORT?
By revenue growth (latest reported year), Artivion, Inc.
(AORT) is pulling ahead at 13. 6% versus 11. 5% for RadNet, Inc. (RDNT). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to -768. 4% for RadNet, Inc.. Over a 3-year CAGR, RDNT leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RDNT or AORT?
RadNet, Inc.
(RDNT) is the more profitable company, earning 2. 3% net margin versus 2. 2% for Artivion, Inc. — meaning it keeps 2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AORT leads at 6. 1% versus 3. 0% for RDNT. At the gross margin level — before operating expenses — AORT leads at 61. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RDNT or AORT more undervalued right now?
On forward earnings alone, RadNet, Inc.
(RDNT) trades at 91. 8x forward P/E versus 98. 7x for Artivion, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RDNT: 60. 0% to $92. 00.
08Which pays a better dividend — RDNT or AORT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is RDNT or AORT better for a retirement portfolio?
For long-horizon retirement investors, Artivion, Inc.
(AORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +188. 9% 10Y return). Both have compounded well over 10 years (AORT: +188. 9%, RDNT: +947. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RDNT and AORT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.